Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Claire on +44 1494 818 025 or claire@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Claire Roberts
Director
claire@zenopa.com
+44 1494 818 025

Testimonials
Zenopa were brilliant from start to finish during my recruitment process. Zenopa are one of the few recruiters that actually listened to my needs and requirements to fit to their needs.
Michael , 2013

Merck Serono and Threshold to co-develop cancer therapy

6 March 2012 00:00 in Pharmaceutical Company Product News


Merck Serono has entered into an agreement with Threshold Pharmaceuticals over the development of a new small molecule hypoxia-targeted drug for oncology applications.

The global agreement will see the companies co-developing and commercialising the compound TH-302, which is currently in phase III development as a soft tissue sarcoma treatment, while phase II studies are also assessing it as a therapy for advanced pancreatic cancer.

Merck will receive co-development and exclusive global marketing rights, while Threshold will have an option to co-commercialise TH-302 in the US.

Threshold will receive an upfront fee of 19 million euros (15.83 million pounds) under the deal, with up to 26.5 million euros in additional payments to be paid in 2012 and a further 15 million euros contingent on results from the pancreatic cancer trial.

Susan Jane Herbert, head of global business development and strategy at Merck Serono, said: "We are excited by the new resources that our partnership is going to bring to the development of TH-302 and the expertise in clinical development and commercialisation that Merck will contribute to this programme."

Last month, Merck Serono agreed a deal to distribute Mendor diabetes technology in the UK market, commencing this month.ADNFCR-8000103-ID-801310382-ADNFCR

Other news stories from 06/03/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd